Water Journal : Water Journal July 2012
wastewater refereed paper technical features 88 JULY 2012 water Overall, consumption audit data are a good predictor of a hospital contribution. They allow screening of pharmaceuticals used in hospitals and identifying those of potential concern that may require monitoring. The consumption-based approach developed in this study represents an additional step towards prioritisation of pharmaceuticals originating from hospital wastewater that is transferrable to other states and countries depending on availability and quality of audit data. Acknowledgements The authors wish to thank the South East Queensland Urban Water Security Research Alliance for their financial support; Queensland Health and the Medication Services Queensland for providing hospital audit data -- and, more specifically, Belinda Allen and Diana Kateley for their support regarding the understanding and processing of the hospital audit data; Greg Jackson from Queensland Health for his helpful comments during this study; Vanna Mabbott and Chris Raymond from the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) (Department of Health and Ageing, Australian Government) for providing statistics on Australian pharmaceutical consumptions and their support during the data processing; and Queensland Urban Utilities for providing information on water consumptions of hospitals and flow data of the STPs investigated. The Authors Dr Kristell Le Corre (email: k.lecorre@ awmc.uq.edu.au) is a Postdoctoral Research Fellow at the Advanced Water Management Centre (AWMC), The University of Queensland, Brisbane, Australia. Dr Christoph Ort (email: Christoph. Ort@eawag.ch) is a Research Scientist in Urban Water Engineering at Eawag, Dübendorf, Switzerland and an Adjunct Research Fellow at the Advanced Water Management Centre (AWMC), The University of Queensland, Brisbane, Australia. Prof Jurg Keller (email: j.keller@uq. edu.au) is the director of the Advanced Water Management Centre (AWMC), The University of Queensland Brisbane, Australia. Full results of this study are published in: Le Corre KS, Kateley D, Allen B, Escher BI, Ort C & Keller J (2012): Consumption- based approach for assessing the contribution of hospitals towards the load of pharmaceutical residues in municipal wastewater. Environment International, 45(1), pp 99--111 (http://dx.doi. org/10.1016/j.envint.2012.03.008). References Aherne GW, Hardcastle A & Nield AH (1990): Cytotoxic drugs and the aquatic environment: estimation of bleomycin in river and water samples. Journal of Pharmacy and Pharmacology, 42 (10), pp 741--742. Anderson AML & Lennox JL (2009): Abacavir/ Lamiduvine fixed dose combination in the treatment of patients with HIV infection. HIV Therapy, 3 (1), pp 19--29. Besse J-P, Latour J-F, Garric J (2012): Anticancer drugs in surface waters: What can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs? Environment International, 39 (1), pp 73--86. Fick J, Soderstrom H, Lindberg RH, Phan C, Tysklind M & Larsson JDG (2009): Contamination of surface, ground, and drinking water from pharmaceutical production. Environmental Toxicology & Chemistry, 28 (12), pp 2522--2527. Hawkshead J (2008): Hospital wastewater containing pharmaceutically active compounds and drug resistant organisms: a source of environmental toxicity and increased antibiotic resistance. Journal of Residuals Science and Technology, 5 (2), pp 51--60. Kümmerer K (2004): Pharmaceuticals in the environment: Sources, fates, effects and risks. Second Edition, Springer, Berlin, Germany. 527pp. McArdell CS, Kovalova L, Siegrist H, Kienle C, Moser R & Schwartz T (2011): Input and elimination of pharmaceuticals and disinfectants from hospital wastewater. Final project report, Eawag, Dübendorf, Switzerland, July 2011; 2011. 95pp. Accessible at: tinyurl.com/eawag- spitalabwasser. Metcalfe CD, Chu S, Judt C, Li H, Oakes KD, Servos MR & Andrews DM (2010): Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershed. Environmental Toxicology & Chemistry, 29 (1), pp 79--89. Monteiro SC & Boxall ABA (2010): Occurrence and fate of human pharmaceuticals in the environment. Reviews of Environmental Contamination and Toxicology, 202, pp 53--154. NRMMC (2008): Australian guidelines for water recycling: Managing health and environmental risks (Phase 2): Augmentation of drinking water supplies, published by the Natural Resource Management Ministerial Council (NRMMC), the Environment and Heritage Council (EPHC) and the National Health and Medical Research Council (NHMRC), Canberra, Australia, 159p. Available at: www.ephc.gov.au/sites/default/ files/WQ_AGWR_GL__ADWS_Corrected_ Final_%20200809.pdf. Accessed: July 2011. HSDP, Highly Specialised Drugs Program (Section 100) of the Australian Pharmaceutical Benefit Scheme (PBS) (2011): Available at: www.pbs. gov.au/info/browse/section-100/s100-highly- specialised-drugs. Accessed: July 2011. Johnson AC, Jürgens MD, Williams RJ, Kümmerer K, Kortenkamp A & Sumpter JP (2008): Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. Journal of Hydrology, 348 (1-2), pp 167--175. Jury KL, Khan SJ, Vancov T, Stuetz RM & Ashbolt NJ (2011): Are sewage treatment plants promoting antibiotic resistance? Critical Reviews in Environmental Science and Technology, 41 (3), pp 243--270. Ort C, Lawrence MG, Reungoat J, Eaglesham G, Carter S & Keller J (2010): Determining the fraction of pharmaceutical residues in wastewater originating from a hospital. Water Research, 44 (2), pp 605--615. Reinthaler FF, Posch J, Feierl G, Wüst G, Haas D, Ruckenbauer G, Mascher F & Marth E (2003): Antibiotic resistance of E. coli in sewage and sludge. Water Research, 37 (8), pp 1685--1690. Sanderson H, Johnson DJ, Reitsma T, Brain RA, Wilson CJ & Solomon KR (2004): Ranking and prioritization of environmental risks of pharmaceuticals in surface water. Regulatory Toxicology and Pharmacology, 39 (2), pp 158--183. TGA (2011): Therapeutic Goods Administration, Australia. www.tga.gov.au Thomas KV, Dye C, Schlabach M & Langford KH (2007): Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. Journal of Environmental Monitoring, 9 (12), pp 1410--1418. Vulliet E, Cren-Olivé C, Grenier-Loustalot M-F (2011): Occurrence of pharmaceuticals and hormones in drinking water treated from surface waters. Environmental Chemistry Letters, 9 (1), pp 103--114. Watts C, Maycock D, Crane M, Fawell J & Gosland E (2007): Desk based review of current knowledge on pharmaceuticals in drinking water and estimation of potential levels. Final report to the Drinking Water Inspectorate, London, UK, 107pp. First accessed on 03/02/2011 at: www.dwi.gov.uk/research/ completed-research/2000todate.htm Webb SF (2004): A data base perspective on the environmental risk assessment of human pharmaceuticals III -- indirect human exposure. In: Pharmaceuticals in the environment: Sources, fates, effects and risks, Kümmerer, K. (Ed), pp 363--372, Second Edition, Springer, Berlin, Germany, 527p.
Water Journal August 2012
Water Journal May 2012